Company Shares of Infinity Pharmaceuticals (NASDAQ:INFI) Rally 2.19%

Infinity Pharmaceuticals (NASDAQ:INFI) has been under a strong bear grip, hence the stock is down -71.36% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.9% in the past 1 week. The stock has risen by 2.19% in the past week indicating that the buyers are active at lower levels, but the stock is down -70.89% in the past 4 weeks.

The company shares have dropped -86.79% from its 1 Year high price. On Jul 14, 2015, the shares registered one year high at $10.92 and the one year low was seen on Jul 6, 2016. The 50-Day Moving Average price is $3.18 and the 200 Day Moving Average price is recorded at $5.36.

The stock has recorded a 20-day Moving Average of 25.03% and the 50-Day Moving Average is 64.02%.


Infinity Pharmaceuticals (NASDAQ:INFI): stock turned positive on Friday. Though the stock opened at $1.31, the bulls momentum made the stock top out at $1.43 level for the day. The stock recorded a low of $1.31 and closed the trading day at $1.4, in the green by 6.06%. The total traded volume for the day was 1,912,172. The stock had closed at $1.32 in the previous days trading.

In an insider trading activity, Perkins Adelene Q, director officer (President & CEO) of Infinity Pharmaceuticals, Inc., unloaded 5,000 shares at an average price of $10.93 on June 25, 2015. The total amount of the transaction was worth $54,650, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies. In addition to duvelisib, the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies), a worldwide investigation of duvelisib in blood cancers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *